5 news items
What's Going On With Molecular Templates Stock?
MTEM
9 Apr 24
and was well-tolerated with no drug-related Grade 4 or Grade 5 adverse events observed.
“We are excited to see objective responses
Molecular Templates Presents Interim Data From MT-6402 Phase I Study In Patients With PD-L1+ Solid Tumors At 2024 AACR Annual Meeting
MTEM
9 Apr 24
confirmed partial responses (one response was unconfirmed at the time of the poster's submission but has subsequently been confirmed). The patients remain
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
MTEM
9 Apr 24
in San Diego, CA, and also announced monotherapy response activity in Head and Neck Cancer. The poster highlighted
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
MTEM
29 Mar 24
and Chief Scientific Officer of MTEM, stated, "We are very excited to see objective responses in heavily pre-treated, checkpoint-experienced head
Molecular Templates, Inc. Provides Interim Update
MTEM
4 Mar 24
responses observed were as follows: three had a partial response ("PR") (two unconfirmed) and a fourth patient had evidence of tumor regression. All four
- Prev
- 1
- Next